£58.0M
General Catalyst led the financing alongside a syndicate of new and existing investors to support the developer of antibody-based therapeutics.
MT
Maxion Therapeutics
Maxion Therapeutics develops antibody-based biologic drugs for ion channel and GPCR-driven diseases.
Cambridge, UK—Founded 2020
£58.0MTotal raised
Maxion Therapeutics develops antibody-based biologic drugs using its proprietary KnotBody platform to target ion channels and G-protein-coupled receptors. The company operates from Cambridge and builds therapies for conditions such as chronic pain and autoimmune disorders.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Shareholders' funds
Members only
Current assets
Members only
Profit for the year
Members only
Cash, assets and headcount from Maxion Therapeutics's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
JM
John McCafferty
Co-founder
Aneesh Karatt-Vellatt
Co-founder
Aneesh is the founder and chief scientific officer at Maxion Therapeutics, and previously co-founded IONTAS. He brings founding and scientific leadership experience from the therapeutics sector.